Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction

Inclusion Criteria: 1. Patients who met the Sepsis-3 criteria, defined by a suspected or confirmed infection and an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline. 2. Patients with a diagnosis of sepsis-induced myocardial dysfunction (SIMD). Exclusion Criteria: 1. Patients with significant primary cardiac diseases, including unstable coronary artery disease, severe cardiomyopathy, or severe valvular heart disease. 2. Exclusion criteria included long-term use of Danhong Injection or recent use of other medication with potential significant impact on cardiac function. 3. Patients with severe hepatic dysfunction (defined as Child-Pugh class C) or severe renal insufficiency (defined as creatinine clearance \<30 mL/min) were excluded. 4. Patients with a known allergy to any component of Danhong Injection or a history of severe allergic diathesis were excluded. 5. Pregnant or lactating women 6. Patients with severe mental illness or inability to cooperate with the study. 7. Participation in other drug clinical trials within 3 months prior to enrollment.